Conference will be held April 22-23 at the Hyatt Regency Cambridge,
NEW YORK, April 8, 2008 /PRNewswire/ -- Gerson Lehrman Group, the world's leading marketplace for expertise, and the Biotechnology Industry Organization (BIO) announced an extension of their partnership with this latest initiative focused on providing the venture investment community, registered to attend the BIO National Venture Conference, with scientific expertise on the most promising early-stage biotechnology innovations.
GLG Council Members, including nationally recognized clinicians and researchers, will be speaking during therapeutic workshops at the inaugural BIO National Venture Conference, along with pharmaceutical and biotechnology industry senior executives to discuss innovative treatment advances in the fields of new antibiotics, RNA-based therapies, and stem cell/regenerative medicine.
"As with our efforts during the prestigious BIO CEO and Investor Conference in February 2008, we are very pleased to join with the Biotechnology Industry Organization to program the only truly independent conference series for healthcare industry decision makers, where the sole focus is premier education," said Alexander Saint-Amand, Chief Executive Officer of Gerson Lehrman Group. "By partnering with BIO and their highly respected investor conference series, Gerson Lehrman Group can make available its unparalleled network of healthcare experts to help educate decision makers in every industry by connecting them to the academic and industry leaders driving innovation and productivity in our global economy."
Through this partnership, BIO will tap into Gerson Lehrman Group's
network of more than 175,000 experts from around the world. The panel
speakers will be specifically identified to focus on some of the most
interesting and novel development areas within the biotechnology industry:
antibiotics, RNA-based therapies, and s
|SOURCE Gerson Lehrman Group|
Copyright©2008 PR Newswire.
All rights reserved